8 November

The trials are coming in. This for those with Type 2 diabetes, assessing whether giving them GLP-1 ‘weight loss’ drugs impacted their progression to neurodegenerative diseases like Alzheimers, Parkinsons and any dementia. The blue line is those on the GLP-1 drugs. Significant slowing of progression. Dementias are some of our largest killers. It’s tantalising that GLP-1 technology may be targeting at last the root mechanism of most of our chronic diseases. As they refine the drugs and treatment regimes for these chronic diseases using GLP-1 (something they weren’t originally designed for), we may even be looking at cures for many of these conditions.